Tags

Type your tag names separated by a space and hit enter

Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Pharmatherapeutica. 1985; 4(2):132-40.P

Abstract

Sixty patients suffering from Parkinson's disease, irrespective of previous treatment, were recruited and treated with benserazide/l-dopa or carbidopa/l-dopa, randomly allocated, in a double-blind comparative study. Duration of disease on entry was 1 year or less in 70% of patients and was graded as moderate in 55% of patients. Mean age of patients on entry was 76 years for males and 80 years for females. Assessments were made before treatment and after 1 week, 3 weeks, 6 weeks and, finally, at 12 weeks. The dosage of drug was titrated at each visit to give minimum risk with acceptable benefit. Both drugs effectively improved the disability scores of the parkinsonian symptoms and the Sheffield Unit's Activities of Daily Living scores, the latter showing the immediate benefit for the patient in terms of independence. More patients improved in the benserazide/l-dopa-treated group. Furthermore, apart from one activity the improvement in each individual symptom and activity was greater in the benserazide/l-dopa-treated group, but none of the differences reached a statistically significant level. Adverse events recorded during the study were few and in many cases transient. Two patients defaulted (1 on each treatment) and 7 patients died during the study from non-drug-related causes.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

4059292

Citation

Admani, A K., et al. "Patient Benefits of L-dopa and a Decarboxylase Inhibitor in the Treatment of Parkinson's Disease in Elderly Patients." Pharmatherapeutica, vol. 4, no. 2, 1985, pp. 132-40.
Admani AK, Verma S, Cordingley GJ, et al. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Pharmatherapeutica. 1985;4(2):132-40.
Admani, A. K., Verma, S., Cordingley, G. J., & Harris, R. I. (1985). Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Pharmatherapeutica, 4(2), 132-40.
Admani AK, et al. Patient Benefits of L-dopa and a Decarboxylase Inhibitor in the Treatment of Parkinson's Disease in Elderly Patients. Pharmatherapeutica. 1985;4(2):132-40. PubMed PMID: 4059292.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. AU - Admani,A K, AU - Verma,S, AU - Cordingley,G J, AU - Harris,R I, PY - 1985/1/1/pubmed PY - 1985/1/1/medline PY - 1985/1/1/entrez SP - 132 EP - 40 JF - Pharmatherapeutica JO - Pharmatherapeutica VL - 4 IS - 2 N2 - Sixty patients suffering from Parkinson's disease, irrespective of previous treatment, were recruited and treated with benserazide/l-dopa or carbidopa/l-dopa, randomly allocated, in a double-blind comparative study. Duration of disease on entry was 1 year or less in 70% of patients and was graded as moderate in 55% of patients. Mean age of patients on entry was 76 years for males and 80 years for females. Assessments were made before treatment and after 1 week, 3 weeks, 6 weeks and, finally, at 12 weeks. The dosage of drug was titrated at each visit to give minimum risk with acceptable benefit. Both drugs effectively improved the disability scores of the parkinsonian symptoms and the Sheffield Unit's Activities of Daily Living scores, the latter showing the immediate benefit for the patient in terms of independence. More patients improved in the benserazide/l-dopa-treated group. Furthermore, apart from one activity the improvement in each individual symptom and activity was greater in the benserazide/l-dopa-treated group, but none of the differences reached a statistically significant level. Adverse events recorded during the study were few and in many cases transient. Two patients defaulted (1 on each treatment) and 7 patients died during the study from non-drug-related causes. SN - 0308-051X UR - https://www.unboundmedicine.com/medline/citation/4059292/Patient_benefits_of_l_dopa_and_a_decarboxylase_inhibitor_in_the_treatment_of_Parkinson's_disease_in_elderly_patients_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -